论文部分内容阅读
目的:探讨多西紫杉醇联合卡铂治疗激素抵抗性前列腺癌的应用价值。方法:12例前列腺癌患者,全部经去势手术及不同程度的抗雄激素药物治疗,经全身骨扫描证实均有多发性骨转移灶,颈部淋巴结转移和肝转移各1例,血PSA呈逐渐上升趋势。给予多西紫杉醇75mg/m2,第一天;卡铂AUC5(300～400 mg/m2),第一天;21—28天为一个周期。结果:12例随访2～26个月,平均17个月。入组后接受治疗1～6个周期。3例患者PSA值降至正常水平<4ng/ml,7例PSA值下降超过50%,有效率83.3%,有效患者PSA从治疗前(67.8±35.9ng/ml)下降至(14.2±5.7ng/ml),有效持续时间6～19个月,平均15.1个月。中位生存期为17.8个月。最常见的毒副反应为骨髓抑制,其余反应均可耐受。结论:多西紫杉醇联合卡铂治疗激素抵抗性前列腺癌有较好疗效,毒副反应可以耐受。
Objective: To investigate the value of docetaxel combined with carboplatin in the treatment of hormone-refractory prostate cancer. Methods: Twelve cases of prostate cancer were treated by castrated surgery and varying degrees of anti-androgen therapy. One case of multiple bone metastases, cervical lymph node metastasis and liver metastasis were confirmed by whole body bone scan. Gradually upward trend. To give docetaxel 75mg / m2, the first day; carboplatin AUC5 (300 ~ 400 mg / m2), the first day; 21-28 days for a cycle. Results: 12 cases were followed up for 2 ~ 26 months with an average of 17 months. Into the group after treatment for 1 to 6 cycles. The PSA value decreased to normal level <4ng / ml in 3 patients, the PSA value dropped more than 50% in 7 patients, the effective rate was 83.3%, the effective PSA decreased from 67.8 ± 35.9ng / ml to 14.2 ± 5.7ng / ml), the effective duration of 6 to 19 months, an average of 15.1 months. The median survival was 17.8 months. The most common adverse reaction is myelosuppression, the rest of the reaction can be tolerated. Conclusion: Docetaxel combined with carboplatin is effective in treating hormone-refractory prostate cancer. Toxicity and side effects can be tolerated.